ArticleChemistry & biodiversity2026
Moringa oleifera Lam. Seed Lectin (WSMoL) Attenuates Parkinsonian Symptoms in Mice via Anti-Inflammatory, Antioxidant, and Neurotransmitter-Modulating Effects.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
This work investigated the effects of Moringa oleifera seed lectin (WSMoL) on motor performance, neuroinflammation, and oxidative stress in a rotenone-induced model of Parkinson's disease (PD). Male mice were daily administered rotenone (3 mg/kg, i.p.) 1 h after being treated with WSMoL (1, 2, or 4 mg/kg, i.p.), levodopa (L-DOPA, 10 mg/kg), or vehicle for 10 days. To assess dopaminergic involvement, another group received the D1 receptor antagonist SCH-23390 co-administered with WSMoL (4 mg/kg). The healthy control group received vehicle only. Motor performance was evaluated using the rotarod, cylinder, and open field tests. Brain levels of monoamines and cytokines as well as redox status were measured. WSMoL prevented the rotenone-related deficits in motor performance, which was accompanied by non-depleted dopamine and serotonin levels. WSMoL also mitigated the increase of IL-6, IL-17A, IFN-γ, and TNF-α. In addition, it prevented oxidative stress by avoiding the exacerbation of superoxide production, lipid peroxidation, and NADPH oxidase activity, while maintaining catalase, superoxide dismutase (SOD), and reduced glutathione (GSH) levels. The data show that D1 receptor-mediated signaling contributes to WSMoL effects. In conclusion, WSMoL attenuates motor deficits and neuroinflammation in a PD model, which supports its potential as a neuroprotective agent and warrants further mechanistic and translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.